ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2699

Optimizing Scleroderma Centers of Excellence: Perspectives from Patients and Scleroderma (SSc) Experts

Veronika K. Jaeger1, Andrew Aubin2, Nancy Baldwin3, Kim Fligelstone4, Robyn Sims5, Joep Welling6, Ryan Burrill7, Kerri Connolly7, Tracy Frech8, Jessica K. Gordon9, Tanaka Ngcozana10, Monika Kowalczyk11, Matthew R. Lammi12, Ulrich A. Walker1 and Lesley Ann Saketkoo13, 1Department of Rheumatology, University Hospital Basel, Basel, Switzerland, Basel, Switzerland, 2Louisiana State University School of Medicine, New Orleans, LA, 3Scleroderma Foundation - Chicago Support Group, Chicago, IL, 4Royal Free Hospital, Scleroderma Unit and Scleroderma Society, London, United Kingdom, 5Scleroderma Australia, Victoria, Australia, 6The Dutch Patient Organization for Systemic Autoimmune Diseases, Utrecht, Netherlands, 7Scleroderma Foundation, Boston, MA, 8Div of Rheumatology, University of Utah, Salt Lake City, UT, 9Rheumatology, Hospital for Special Surgery, New York, NY, 10Rheumatology Department, Lower, Royal Free hospital, London, United Kingdom, 11DIvision of Gastroenterology, Tulane University School of Medicine, New Orleans, LA, 12Louisiana State University Health Sciences Center, Pulmonary and Critical Medicine, New Orleans, LA, 13Scleroderma and Sarcoidosis Patient Care and Research Center, Rheumatology and Pulmonary Medicine, Louisiana State University Health Sciences Center, New Orleans, LA

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: patient engagement, quality improvement, quality of care, scleroderma and systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Clinical Aspects and Therapeutics: Determinants of Disease, Classification and Response

Session Type: Abstract Submissions (ACR)

Background/Purpose:   SSc is a complex, diffuse, devastating health condition of vascular injury, inflammation and fibrosis resulting in multiple organ-system derangements with high impact on survival and quality of life.  Demonstrated research activity tends to define SSc Centers of Excellence (SCoE) certification.  However, SSc complications require coordinated high-level multi-specialty expert care. The Scleroderma Foundation in partnership with Scleroderma Australia and Scleroderma Society UK engaged SSc patients and SSc health providers (HPs) in a multi-tiered process to assess priorities in recognition of SCoEs.

Methods:   A mixed methods design ensured comprehensive item collection in addressing ‘important qualities and services in a certified SSc Center of Excellence’.  A core of 35 patients, SSc HPs from 8 countries initiated the study through an iterative process using nominal group technique with rounds of item collection modification and review until saturation and satisfaction of proposed survey content was achieved and subsequently field-tested with a 5 point scale (critical to low importance). Participation was screened and ‘gate-controlled’ with online survey access through a unique one-time link. Telephone interview was offered for accessibility.  Responses from SSc patients and HPs were compared by Pearson’s Χ2 or Fisher’s exact tests as appropriate.

Results: Initial phases yielded a 54 item survey that was field-tested in 15 SSc patients and HPs. 400 patients and SSc HPs received surveys of which 299 from 19 countries (75% response rate) were completers.  Expert care superseded research as a priority of ‘critical importance’ by HPs and patients respectively at 69% and 48% (p=0.02) and by 94% and 89% (p=0.8) when ‘critical to very important’ were collapsed.  3 questions provided internal cross-validation of this query.  “SCoEs should engage in research” received 57% of patients and 48% of HPs (p=0.37) as being critical.   Further, education, rehabilitative services and support networks were consistently highly rated items with topics stratified by ratings (tables 1 & 2). Discrepant areas of importance between patients and HPs are highlighted in tables.

Conclusion:   Participation was robust in all project stages emphasizing the perceived global importance of this effort.  Though research is of clear importance, quality expert care incorporating rehabilitative and educational provisions is a SCoE operational priority. These findings signal the need to redefine SCoE certification standards and provide a roadmap to SCoE development.

ACR 2014 Centers of Excellence Table 1.jpg

ACR 2014 Centers of Excellence Table 2.jpg

 


Disclosure:

V. K. Jaeger,
None;

A. Aubin,
None;

N. Baldwin,
None;

K. Fligelstone,
None;

R. Sims,
None;

J. Welling,
None;

R. Burrill,
None;

K. Connolly,
None;

T. Frech,
None;

J. K. Gordon,
None;

T. Ngcozana,
None;

M. Kowalczyk,
None;

M. R. Lammi,
None;

U. A. Walker,
None;

L. A. Saketkoo,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/optimizing-scleroderma-centers-of-excellence-perspectives-from-patients-and-scleroderma-ssc-experts/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology